Drug intelligence / Profile preview

D501

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

D501 refers to a specific batch of adefovir dipivoxil tablets. Adefovir dipivoxil is an antiviral nucleotide analogue prodrug that is orally absorbed and subsequently converted to its active form, adefovir. This active form inhibits viral DNA polymerase. The D501 batch was evaluated in a study for its in vitro dissolution rate and in vivo bioavailability in dogs, demonstrating a faster dissolution rate compared to other tested batches.

Targets

DNA polymerase family

Beyond the preview

Go deeper on D501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D501.

Explore the full profile